The global oncology landscape has once again turned its attention to CDH17, a promising target in solid tumor research. On October 17, Hansoh Pharma announced a landmark licensing agreement with Roche for HS-20110, a CDH17-targeting antibody-drug conjugate (ADC), marking another milestone for China’s innovative drug exports. The transaction, valued at up to USD 1.45 billion, includes an upfront payment of USD 80 million and subsequent milestone payments linked to development, regulatory, and commercialization progress. Hansoh retains the rights for Greater China and will receive tiered royalties from future global sales.Learn more about our CDH17 catalog.
This collaboration represents not only a major international endorsement of Hansoh Pharma’s R&D capabilities but also reflects the growing recognition of China’s biotechnology innovation on the global stage. HS-20110, currently in global Phase I clinical trials, is designed to treat colorectal cancer and other solid tumors, addressing significant unmet clinical needs. Roche’s decision to invest heavily in this partnership underscores the rising strategic importance of novel ADC targets such as CDH17, which are driving a new wave of precision oncology.
CDH17, or Cadherin-17, has emerged as a highly specific biomarker associated with gastrointestinal and other epithelial-derived cancers. Its restricted expression in normal tissues and high expression in tumor cells make it an attractive candidate for targeted therapies, including ADCs, bispecific antibodies, and CAR-T cell approaches. The Hansoh–Roche collaboration not only validates CDH17’s potential as a therapeutic target but also signals an accelerating trend toward expanding the ADC target landscape beyond traditional antigens.
As interest in CDH17 continues to grow, reliable preclinical models and cell-based systems are becoming critical to accelerate translational research and drug development. At Genomeditech, we are proud to support this momentum through a comprehensive suite of ready-to-use CDH17-expressing cell lines and related assay tools. Our validated CDH17 cell models are optimized for:
Target validation and mechanism-of-action studies
Efficacy evaluation in ADC and biologic development
High-throughput screening and preclinical assay design
These tools empower oncology researchers to efficiently advance discovery programs, derisk preclinical studies, and facilitate cross-laboratory reproducibility. By bridging innovative science with practical research solutions, Genomeditech contributes to the global effort of translating CDH17 biology into meaningful therapeutic breakthroughs.
The Hansoh–Roche partnership stands as a powerful example of cross-border collaboration reshaping oncology R&D. As CDH17 moves further into the global spotlight, having robust and reproducible research tools will be essential for sustaining this innovation wave. Genomeditech remains committed to equipping scientists with high-quality cellular models that drive the next generation of precision oncology.
